ArticleActa histochemica et cytochemica2026
Heterogeneous Expression of TREM2 And STAB1 Among Tumor-Associated Macrophages in Clear-Cell Renal Cell Carcinoma.
Article in Acta histochemica et cytochemica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tumor-associated macrophages (TAMs) play important roles in shaping the tumor microenvironment and regulating antitumor immune responses. Triggering receptor expressed on myeloid cells 2 (TREM2) and stabilin-1 (STAB1/CLEVER1) have recently attracted attention as molecules associated with immunosuppressive macrophage phenotypes; however, their expression patterns in clear-cell renal cell carcinoma (ccRCC) remain unclear. This study aimed to examine TREM2 and STAB1 expression in ccRCC using public transcriptomic datasets and public single-cell RNA sequencing data, as well as immunohistochemistry using ccRCC specimens. In the TCGA cohort, high TREM2 and STAB1 mRNA expression was associated with poor overall survival and advanced tumor stage. In an independent immunohistochemistry cohort, TREM2 was expressed mainly in TAMs, whereas STAB1 was expressed in both TAMs and endothelial cells. TREM2-positive TAM density was significantly associated with high nuclear grade, whereas STAB1-positive TAM density was not. Double immunohistochemistry and single-cell RNA sequencing analyses suggested different, but partially overlapping, expression patterns of TREM2 and STAB1 among TAMs. TREM2-high TAMs showed features of monocyte-derived macrophages, whereas STAB1-high TAMs showed features associated with tissue-resident macrophages. These findings suggest that TREM2-positive TAMs and STAB1-positive TAMs contribute differently to the immune microenvironment of ccRCC. Further studies are needed to clarify their functional significance and therapeutic potential.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.